Sie sind bereits registriert?
Loggen Sie sich mit Ihrem Universimed-Benutzerkonto ein:
Sie sind noch nicht registriert?
Registrieren Sie sich jetzt kostenlos auf universimed.com und erhalten Sie Zugang zu allen Artikeln, bewerten Sie Inhalte und speichern Sie interessante Beiträge in Ihrem persönlichen Bereich
zum späteren Lesen. Ihre Registrierung ist für alle Unversimed-Portale gültig. (inkl. allgemeineplus.at & med-Diplom.at)
A Potential New Treatment Option for Chemotherapy-Refractory Gastric Cancer
For patients with metastatic esophagogastric adenocarcinoma, inhibition of the vascular endothelial growth factor (VEGF) pathway via the anti–VEGFR-2 antibody ramucirumab increases response, progression-free survival (PFS) and overall survival (OS) when combined with second-line treatment with paclitaxel. The multitargeted tyrosine kinase inhibitor regorafenib targets VEGFR and other pathways and has effectiveness in chemotherapy-refractory colorectal cancer.
Investigators now report results of the industry-sponsored, randomized, double-blind, placebo-controlled INTEGRATE IIa trial evaluating regorafenib (160 mg daily for 21 days of 28-day cycles) in patients with chemotherapy-refractory esophagogastric adenocarcinoma. Of the 251 patients enrolled, 63% were treated in Asia; 73% had gastric primaries; 42% had received a prior VEGF inhibitor; 59% had received two and 40% had received three or more lines of prior chemotherapy. For the analysis of OS, the primary endpoint, results were pooled with those from INTEGRATE I, a prior randomized, placebo-controlled, phase II trial in 147 patients.
At a median follow-up of 48 months, OS was improved with regorafenib over placebo in the pooled cohort (hazard ratio, 0.70; P=0.001) and in the INTEGRATE IIa cohort (HR, 0.68; P=0.006). In the INTEGRATE IIa cohort, 1-year OS was improved with regorafenib (19% vs. 6%), whereas median OS was similar (4.0 and 4.5 months). PFS was improved with regorafenib (HR, 0.53; P<0.0001). The disease control rate was higher with regorafenib than placebo (21.3% vs. 4.9%) and the antitumor response was limited (2.4% vs. 0%). Adverse events related to regorafenib, including palmar–plantar erythrodysesthesia, mucositis, hypertension, and diarrhea, were manageable.
Comment
INTEGRATE IIa indicates a modest improvement in OS and PFS with regorafenib, and limited antitumor responses, in patients with chemotherapy-refractory esophagogastric adenocarcinoma. Regorafenib may emerge as another therapeutic option in these patients, in addition to the recently FDA-approved option of trifluridine tipiracil. We await results for the combination of nivolumab and regorafenib in chemotherapy-refractory disease.
Citation(s)
Author:
Pavlakis N et al.
Title:
INTEGRATE IIa phase III study: Regorafenib for refractory advanced gastric cancer.
Source:
J Clin Oncol
2024
Oct
4; [e-pub].
(Abstract/FREE Full Text)
Empfohlen von
David H. Ilson, MD, PhD